As a key glycolytic enzyme, NSE is mainly expressed in neuroendocrine tumors but rarely expressed in NSCLC, except for in patients with neuroendocrine differentiation, which accounts for approximately 10% of NSCLC patients.51, 52, 53, 54. Here, ENO2 is linked to non-small cell lung carcinoma.